Compare
Advanced Biomed Inc. vs Renalytix plc vs BioNexus Gene Lab Corp vs Aclarion, Inc.
| Latest fiscal year | Advanced Biomed Inc. ADVB | Renalytix plc RNLXYLast annual report: year ended 2024-06-30 | BioNexus Gene Lab Corp BGLC | Aclarion, Inc. ACON |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2024-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $2.29M | $7.42M | $75.7K |
| Revenue growth (YoY) | n/a | -32.7% | -21.9% | +65.6% |
| Gross margin | n/a | 6.8% | 14.6% | 9.0% |
| Operating margin | n/a | n/m | -39.9% | n/m |
| Net margin | n/a | n/m | -40.2% | n/m |
| Net income | -$3.26M | -$33.46M | -$2.98M | -$7.23M |
| EPS (Diluted) | -$0.16 | -$0.31 | n/a | -$13.61 |
| Operating cash flow | -$5.83M | -$30.11M | -$1.84M | -$7.16M |
| Free cash flow | -$5.86M | n/a | -$1.88M | -$7.19M |
| Cash & equivalents | n/a | $4.68M | $2.49M | $12.02M |
| Total assets | $6.51M | $7.97M | $9.25M | $13.67M |
| Total liabilities | $3.03M | $15.83M | $637.9K | $837.3K |
| Shareholders' equity | $3.48M | -$7.85M | $8.61M | $12.84M |
| Return on year-end equity | -93.7% | n/a | -34.6% | -56.4% |
| Shares outstanding | 21.64M | 154.37M | 2.42M | 854.4K |
Revenue, most recent five fiscal years
| Fiscal year | Advanced Biomed Inc. | Renalytix plc | BioNexus Gene Lab Corp | Aclarion, Inc. |
|---|---|---|---|---|
| Latest | n/a | $2.29M Ended 2024-06-30 | $7.42M Ended 2025-12-31 | $75.7K Ended 2025-12-31 |
| 1 year earlier | n/a | $3.40M Ended 2023-06-30 | $9.51M Ended 2024-12-31 | $45.7K Ended 2024-12-31 |
| 2 years earlier | n/a | $2.97M Ended 2022-06-30 | $9.77M Ended 2023-12-31 | $75.4K Ended 2023-12-31 |
| 3 years earlier | n/a | $1.49M Ended 2021-06-30 | $10.93M Ended 2022-12-31 | $60.4K Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2020-06-30 | $13.36M Ended 2021-12-31 | $60.3K Ended 2021-12-31 |